A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlobeImmune
With
Memorial Sloan Kettering Cancer Center
NSCLC is the deadliest form of human cancer, killing approximately 150,000 people a year in the United States. The best treatment for NSCLC is surgical resection. For patients with inoperable or unresectable NSCLC chemotherapy and radiation is used as first line therapy. This is a consolidation therapy trial evaluating GI-4000 in subjects with NSCLC treated with curative intent who are disease free at their first post-treatment restaging assessment. These subjects must also have a ras mutation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically proven stage I-III NSCLC
Confirmed product related ras mutation
ECOG performance status of less than or equal to 2
greater than or equal to 18 years of age
You may not be if
History of a previous cancer
History of splenectomy
History of Crohns disease or ulcerative colitis
History of major organ transplantation
Concurrent or chronic steroid therapy
History of allergy to yeast
Presence of an unstable or poorly controlled medical condition